Aptamer Presenting at ASGCT Annual Meeting

Aptamer

29/04/2025 07:00

RNS Number : 5154G

Aptamer Group PLC

29 April 2025

 

 

29 April 2025

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Aptamer Presenting at ASGCT Annual Meeting

 

New Data on Optimer® Delivery Vehicle Targeting Fibrotic Liver

 

Aptamer Group plc (AIM: APTA), the leading developer of next generation synthetic binders delivering innovation to the life science industry, today announces that it will present new data showcasing its proprietary Optimer® delivery vehicle targeting fibrotic liver at the upcoming 2025 American Society for Gene and Cell Therapy (ASGCT) Annual Meeting, to be held from 13 - 17 May 2025 in New Orleans, Louisiana.

 

Dr David Bunka, Aptamer's Chief Scientific Officer, will present the latest advances regarding Aptamer's proprietary Optimer® delivery vehicle, demonstrating its precision-targeting capabilities for fibrotic liver disease - a major unmet clinical need with significant commercial potential.  The new data will show how the Optimer® delivery vehicle enables targeted delivery of RNAi therapies specifically to activated hepatic stellate cells, the key drivers of liver fibrosis.

 

Current gene therapies face well-documented barriers in achieving cell-specific targeting, intracellular uptake, and endosomal escape. Optimer® delivery vehicles are designed to overcome each of these challenges, unlocking new possibilities for effective, tissue-specific gene therapies across a wide range of chronic diseases.

 

This targeted delivery technology has the potential to enhance therapeutic efficacy, reduce off-target effects, and broaden the clinical utility of gene therapies, addressing a critical barrier in RNAi drug development.

Presentation details

Title: Targeted Delivery of siRNA to Activated Hepatic Stellate Cells Using Aptamers: A Novel Approach for Fibrotic Liver Treatment

Session Title: Oligonucleotide Therapeutics (including siRNAs, aptamers, antagomirs, miRNAs, shRNA, antisense, splice switching oligos, plasmids)

Session Date and Time: Wednesday, 14 May 2025, 5:30 pm - 7:30 pm

Location: New Orleans Ernest N. Morial Convention Center, New Orleans, USA

Abstract Presentation Number: 1147

Presenting Author: Dr David Bunka, Aptamer Group, Windmill House, Innovation Way, York, YO10 5BR, UK

- Ends -

  

For further information, please contact: 

 

Aptamer Group plc
Dr Arron Tolley, Chief Executive Officer
+44 (0) 1904 217 404
SPARK Advisory Partners Limited - Nominated Adviser
Andrew Emmott / Jade Bayat
+44 (0) 20 3368 3550
Turner Pope Investments (TPI) Limited - Broker
James Pope / Andrew Thacker
+44 (0) 20 3657 0050
Northstar Communications Limited - Investor Relations
Sarah Hollins
+44 (0) 113 730 3896

 

About Aptamer Group

Aptamer Group is a leading developer of next generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.

 

Aptamer operates a fee-for-service business in the $210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.

 

Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.

 

To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRAIPMLTMTJTBAA